MiniMed Group, Inc. (NASDAQ:MMED) will release its first quarter earnings report before the opening bell on Tuesday, Sept. 1.
Analysts expect the Northridge, California-based company to report quarterly earnings of 9 cents per share, versus 35 cents per share in the year-ago period. The consensus estimate for MiniMed Group’s quarterly revenue is $828.43 million. It reported $3.03 billion last year, according to Benzinga Pro.
On June 29, MiniMed named Alcon CEO David Endicott and Linnea Burman to its board of directors.
Shares of MiniMed Group rose 0.1% to close at $19.51 on Thursday.
Benzinga readers can access the latest analyst ratings on the Analyst Stock Ratings page. Readers can sort by stock ticker, company name, analyst firm, rating change or other variables.
Let’s have a look at how Benzinga’s most-accurate analysts have rated the company in the recent period.
- Wells Fargo analyst Larry Biegelsen maintained an Overweight rating and cut the price target from $26 to $22 on June 4, 2026. This analyst has an accuracy rate of 66%.
- B of A Securities analyst Travis Steed maintained a Buy rating and slashed the price target frm $27 to $20 on May 18, 2026. This analyst has an accuracy rate of 55%.
- Barclays analyst Matt Miksic initiated coverage on the stock with an Overweight rating and a price target of $26 on April 1, 2026. This analyst has an accuracy rate of 64%.
- William Blair analyst Steven Lichtman initiated coverage on the stock with an Outperform rating on March 31, 2026. This analyst has an accuracy rate of 56%.
- Citigroup analyst Joanee Wuensch initiated coverage on the stock with a Buy rating and a price target of $23 on March 31, 2026. This analyst has an accuracy rate of 71%.
Considering buying MMED stock? Here’s what analysts think:
Photo via Shutterstock
